左乙拉西坦(Levetiracetam) - 药物靶点：SV2A_在研适应症：Dravet综合征，癫痫，癫痫发作_专利_临床

概要

基本信息

简介左乙拉西坦 (Levetiracetam) 是一种小型分子实体，已被设计用于将突触小泡蛋白 2A (SV2A) 作为调节靶标。这种药物化合物是 UCB SA 辛勤努力的成果，并于 1999 年 11 月获得首次批准。在医学领域，左乙拉西坦被广泛用作治疗癫痫的抗惊厥药。已知该化合物通过减少患者癫痫发作的频率和强度而表现出抗惊厥特性。 Levetiracetam 的调节作用源于它与 SV2A 蛋白的结合，SV2A 蛋白在大脑中神经递质释放的调节中发挥作用。此外，该化合物良好的副作用特征及其对患者的显着耐受性使其成为癫痫治疗的常用选择。

药物类型

小分子化药

别名

Levetiracetam (JAN/USP/INN)、Levetiracetame、AGB-101

+ [19]

靶点

SV2A

作用机制

SV2A调节剂(突触囊泡蛋白2A调节剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Ratiopharm GmbHPharmathen SASun Pharmaceutical Industries (Europe) BV

+ [16]

非在研机构

UCB Pharma GmbHUCB Pharma BV

Closure Medical Corp.

最高研发阶段批准上市

首次获批日期

美国 (1999-11-30),

癫痫部分性发作

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看首次获批时间轴

结构

分子式C8H14N2O2

InChIKeyHPHUVLMMVZITSG-LURJTMIESA-N

CAS号102767-28-2

关联

431

项与左乙拉西坦相关的临床试验

NCT05986721 / Not yet recruiting临床3期

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101 on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease in Apolipoprotein E4 Non-carriers

The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by reduction in neuronal injury in participants with mild cognitive impairment due to Alzheimer's Disease. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by the Clinical Dementia Rating Scale- Sum of Boxes and Memory Box score.

开始日期2024-12-01

申办/合作机构

AgeneBio, Inc.

NCT06345495 / Not yet recruiting临床2期IIT

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

开始日期2024-09-30

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

CTRI/2024/05/067855 / Not yet recruiting临床3期

Role of prophylactic Levetiracetam on seizure prevention in children during post CPR recovery phase -A Randomized(Double Blinded)Controlled Trial - REAP trial

开始日期2024-06-04

申办/合作机构

All India Institute of Medical Sciences Raipur

100 项与左乙拉西坦相关的临床结果

登录后查看更多信息

100 项与左乙拉西坦相关的转化医学

登录后查看更多信息

100 项与左乙拉西坦相关的专利（医药）

登录后查看更多信息

5,132

项与左乙拉西坦相关的文献（医药）

2024-04-01·Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

Prophylactic removal of a migratory missile from the cerebral ventricles: case report

Article

作者: Cohen, Alan R ; Kalluri, Anita L ; Materi, Joshua ; Ahmed, A Karim ; Ammar, Adam

BACKGROUND AND IMPORTANCE:

Nonpowder firearm injuries to the head pose major health risks, with retained fragments potentially causing harmful sequelae that require neurosurgical intervention.

CLINICAL PRESENTATION:

We report the case of 2-year-old girl who sustained an accidental gunshot wound to the head. She sustained a penetrating ballistic intracranial injury caused by a BB shot from a rifle. At presentation, she was neurologically intact with a punctate laceration on her left forehead. Head CT demonstrated a small depressed left frontal skull fracture, a small intracerebral hematoma, and a 5-mm metallic bullet fragment in the deep left frontal lobe near the frontal horn of the left lateral ventricle. She was admitted to the hospital and managed nonoperatively with levetiracetam and intravenous antibiotics, and discharged home in good condition. Follow-up CT in 1 week showed slight migration of the metallic bullet fragment to the left, placing it at the anterior horn of the lateral ventricle. Six weeks later, follow-up CT showed migration of the bullet to the temporal horn of the left lateral ventricle. Intraventricular migration of the bullet raised concern that it could move further to obstruct the foramen of Monro or cerebral aqueduct. Therefore, we removed the bullet through a small left temporal craniotomy with image guidance using a microsurgical approach through a translucent tube.

CONCLUSION:

The authors discuss the rationale and technique for removing a nonpowder firearm bullet that has migrated within the cerebral ventricles.

2024-03-15·Clinical cancer research : an official journal of the American Association for Cancer Research

Levetiracetam: A Potent Sword against Microglia Polarization in Gliomas

Article

作者: Wang, Qixue ; Kang, Chunsheng ; Cui, Xiaoteng ; Liu, Xiaomin

Summary:

Crosstalk between tumor cells and peritumoral cells contributes to immunosuppressive microenvironment formation in glioblastomas (GBM). A recent study revealed that glioma stem cells activated neuronal activity to promote microglial M2 polarization, leading to GBM progression, which could be pharmacologically blocked by levetiracetam, providing a practical strategy for GBM immunotherapy.See related article by Guo et al., p. 1160

2024-03-01·Epilepsy & behavior : E&B

Greater need for treatment optimization in patients with epilepsy initiating adjunctive therapy: Results of a retrospective claims analysis of antiseizure medication drug load in the United States

Article

作者: Schabert, Vernon F ; Becker, Danielle A ; Wade, Clarence T ; Weingarten, Mindl ; Labiner, David M ; Connor, Gregory S ; Stern, Sean

BACKGROUND:

This retrospective, observational study used US claims data to assess changes in antiseizure medication (ASM) drug load for a cohort of patients with epilepsy.

METHODS:

Adults (≥18 years) with a diagnosis of epilepsy (ICD-10 code G40.xxx) who started new adjunctive ASM treatment with one of 4 branded (brivaracetam, eslicarbazepine, lacosamide, perampanel) or 4 unbranded (carbamazepine, lamotrigine, levetiracetam, topiramate) ASMs between January 1, 2016 and December 31, 2020 were identified from IBM MarketScan® research databases (primary study population). Patients must have been continuously enrolled 360 days before the start of the new ASM (eligibility period). Follow-up was from the start of new ASM until Day 540 (∼18 months). The primary endpoint was concomitant ASM drug load, which included all ASMs except the new (comparator) ASM. A sensitivity analysis population included adults with epilepsy who were continuously enrolled for ≥ 180 days during at least one calendar year in the study period (2016-2020), whether or not the comparator ASM was new or existing during that period. Total ASM drug load, which included comparator ASM and concomitant ASMs, was assessed in the sensitivity analysis population.

RESULTS:

In total, 21,332 patients were included in the primary study population, of which 5767 initiated branded ASMs and 15,565 initiated unbranded ASMs. A total of 392,426 patients were included in the sensitivity analysis population during at least one calendar year 2016-2020. Concomitant ASM drug load increased in the 360 days prior to new ASM start and slightly declined thereafter. Mean concomitant ASM drug load for the primary population was 1.6 (SD 1.8) at new ASM start. Concomitant drug load was higher among those starting branded ASM comparators compared to those starting unbranded comparators. Mean total ASM drug load for patients increased over time and was approximately double for patients exposed to branded ASMs (mean range 2.1 to 2.7) compared to that of patients exposed to any unbranded ASM (mean range 1.0 to 1.3).

CONCLUSION:

Concomitant ASM drug load increased prior to addition of new ASM, with higher increases observed among patients starting branded vs unbranded ASMs, followed by slight decreases thereafter. Total drug load increased linearly among all patients. These findings underscore the need for ongoing ASM regimen evaluation and treatment optimization in patients with epilepsy.

173

项与左乙拉西坦相关的新闻（医药）

2024-06-25

·Science Daily

Your future medications could be personalized for you on a 3D printer

Scientists are helping to develop standards and safety protocols that would allow pharmacies to print drugs onsite at a dosage best for you. Chocolate-flavored pills for children who hate taking medicine. Several drugs combined into one daily pill for seniors who have trouble remembering to take their medications. Drugs printed at your local pharmacy at personalized dosages that best suit your health needs. These are just a few potential advantages of 3D drug printing, a new system for manufacturing drugs and treatments on-site at pharmacies, health care facilities and other remote locations. In 2015, the Food and Drug Administration approved the first 3D-printed drug, Spritam (levetiracetam), for epilepsy. Several other manufacturers and drug companies are developing their own ones. But the widespread adoption of 3D drug printing will require stringent quality control measures to ensure that people get the right medication and dosage. Even a tiny mismeasurement of a drug's ingredient during the printing process could endanger a patient's health. In a new research paper, NIST research scientist Thomas P. Forbes assesses various approaches to ensuring that 3D drug printers work as designed. The journal article applies a "quality by design" analysis to evaluate the best procedures and protocols to ensure that 3D printers produce drugs at the correct dosages and with the correct mix of chemicals. Though various methods exist for remotely printing drugs, Forbes focused on one of the most common: inkjet printers and similar systems that can print personalized medication on demand. Like inkjet printers in homes, though larger, the printer has nozzles that deposit the drug's liquified materials, or inks, into tiny wells on a tray or directly into capsules. Through freeze-drying and other processes, the liquid can be turned into a tablet or powder poured into a capsule. It can also be evaporated onto a thin film that dissolves in the mouth. Forbes' paper does not make any recommendations. Instead, his research identifies and tests several possible methods and techniques for maintaining quality control in 3D drug printing.

上市批准

2024-06-24

·drugs

Anti- Seizure Meds Are Crucial, But Can Trigger Severe Reactions

MONDAY, June 24, 2024 -- Specific steps can be taken to reduce the risk of potentially fatal reactions to anti-seizure medications, researchers report in a new review. Performing blood tests, asking patients about risk factors and modifying dosages all can reduce reaction risk for drugs that millions of Americans take for epilepsy and other conditions, researchers said. However, rashes and skin reactions in newly medicated patients still require prompt medical attention, results show. Rashes are common with anti-seizure meds, occurring in 2% to 16% of patients, depending on the drug, researchers said in background notes. Roughly 5% of these rashes indicate a life-threatening condition, researchers added. The FDA recently issued a warning about serious reactions to two anti-seizure drugs, levetiracetam and clobazam , the researchers noted. “Dangerous reactions are rare, but patients and caregivers should understand the risk and how to respond if side effects occur,” said lead researcher Dr. Ram Mani , chief of the adult epilepsy division at Rutgers Robert Wood Johnson Medical School in New Jersey. For the new report, published recently in the journal Current Treatment Options in Neurology , researchers analyzed and combined published data on individual anti-seizure drugs, distinguishing the different rashes and their triggers. Genetics can increase a person’s risk of a severe rash, as can interactions between the anti-seizure meds and other drugs, researchers found. Users also are at higher risk if they use aromatic anti-seizure drugs like phenobarbital or carbamazepine , or if doctors rapidly escalate the dosage of their med. A common rash typically affects the torso or limbs with a flat rash or hive-like bumps that occur within two weeks of treatment, researchers said. This rash typically disappears without treatment a few weeks after patients stop taking the drug. But while rare, severe skin conditions also can occur. Stevens-Johnson syndrome and toxic epidermal necrolysis can cause fever, eye pain and detached skin, and it often requires hospitalization. “Patients should seek medical treatment if rashes develop rather than waiting for them to disappear,” said researcher Dr. Cindy Wassef , an assistant professor of dermatology at Robert Wood Johnson Medical School. “If symptoms are mild, they can contact their neurologist or primary care physician, but serious symptoms like a high fever, skin pain, or blisters warrant a trip to the emergency room or a 911 call.” Several thousand patients suffer severe reactions to anti-seizure meds each year, Mani estimated. Those numbers could improve if neurologists take the time to suss out high-risk patients and put them on low-risk drugs. “I gave a talk on this topic at the American Epilepsy Society Conference last year, and I asked the more than 200 doctors in the room how frequently they perform the recommended HLA screening tests on indicated patients, and only a handful raised their hands,” Mani said in a Rutgers news release. “So, there’s definitely room for improvement to increase patient safety.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-06-24

·信狐药迅

仿制药申请12个品规、进口上市4个品规发通知件；临床申请品种均默示许可| 新获批（6.17-6.23）

每周药品注册获批数据，分门别类呈现，一目了然。(6.17-6.23）新药上市申请药品名称企业注册分类受理号TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200026国;CXHS2200026TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200025国;CXHS2200025TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200024国;CXHS2200024甲磺酸奥瑞替尼片南京圣和药业股份有限公司1CXHS2101058国;CXHS2101058 新药临床申请药品名称企业注册分类受理号HRS-9813片广东恒瑞医药有限公司1CXHL2400397HRS-9813片广东恒瑞医药有限公司1CXHL2400396PZH2113 胶囊漳州片仔癀药业股份有限公司1CXHL2400372PZH2113 胶囊漳州片仔癀药业股份有限公司1CXHL2400371WD-890片浙江文达医药科技有限公司1CXHL2400361WD-890片浙江文达医药科技有限公司1CXHL2400360WD-890片浙江文达医药科技有限公司1CXHL2400359WD-890片浙江文达医药科技有限公司1CXHL2400358ZX-8177片南京征祥医药有限公司1CXHL2400347ZX-8177片南京征祥医药有限公司1CXHL2400346西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400342西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400341RS-C1001片青岛睿森生物科技有限公司1CXHL2400340RS-C1001片青岛睿森生物科技有限公司1CXHL2400339PH009-1片苏州浦合医药科技有限公司1CXHL2400336PH009-1片苏州浦合医药科技有限公司1CXHL2400335CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400334CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400333CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400332CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400331HRS-7249注射液上海拓界生物医药科技有限公司1CXHL2400329BC-007默化(无锡)生物科技有限公司1CXHL2400326GFH375片劲方医药科技(上海)有限公司1CXHL2400328GFH375片劲方医药科技(上海)有限公司1CXHL2400327注射用WP1302百明信康生物技术(浙江)有限公司1CXHL2400318洛索洛芬钠凝胶贴膏海南赛立克药业有限公司4CYHL2400073注射用BL-M17D1成都百利多特生物药业有限责任公司1CXSL2400237重组抗HER3人源化单抗注射液上海生物制品研究所有限责任公司1CXSL2400232注射用LM-2417礼新医药科技(上海)有限公司1CXSL2400223AK129注射液康方汇科(上海)生物有限公司1CXSL2400220CM355北京天诺健成医药科技有限公司1CXSL2400217IMC-002宜明凯尔生物医药技术(上海)有限公司1CXSL2400219IMC-002宜明凯尔生物医药技术(上海)有限公司1CXSL2400216注射用SKB518四川科伦博泰生物医药股份有限公司1CXSL2400215注射用MK-2870默沙东研发(中国)有限公司1CXSL2400214司美格鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400241司美格鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400240LPS-001注射液乐普药业股份有限公司3.3CXSL2400231QL2108注射液齐鲁制药有限公司3.3CXSL2400221泰它西普注射液荣昌生物制药(烟台)股份有限公司2.1;2.2CXSL2400213 仿制药申请药品名称企业注册分类受理号盐酸异丙肾上腺素注射液成都欣捷高新技术开发股份有限公司3CYHS2301346盐酸异丙肾上腺素注射液成都欣捷高新技术开发股份有限公司3CYHS2301345甲硫酸新斯的明注射液陕西丽彩药业有限公司3CYHS2300705甲硫酸新斯的明注射液陕西丽彩药业有限公司3CYHS2300704美索巴莫注射液南京赛瑞谱顿制药有限公司3CYHS2300368盐酸非索非那定干混悬剂济川药业集团有限公司3CYHS2201943国;CYHS2201943盐酸非索非那定干混悬剂济川药业集团有限公司3CYHS2201942国;CYHS2201942盐酸氨溴索滴剂丽彩甘肃西峰制药有限公司3CYHS2201844国;CYHS2201844盐酸氨溴索滴剂丽彩甘肃西峰制药有限公司3CYHS2201843国;CYHS2201843盐酸左沙丁胺醇雾化吸入溶液宏越科技(湖州)有限公司3CYHS2201800国;CYHS2201800盐酸左沙丁胺醇雾化吸入溶液宏越科技(湖州)有限公司3CYHS2201799国;CYHS2201799己酮可可碱注射液江西和盈药业有限公司3CYHS2201773国;CYHS2201773铝碳酸镁混悬液杭州民生健康药业股份有限公司3CYHS2201508国;CYHS2201508利伐沙班细粒剂浙江恒研医药科技有限公司3CYHS2201485国;CYHS2201485利伐沙班细粒剂浙江恒研医药科技有限公司3CYHS2201484国;CYHS2201484人纤维蛋白原广东双林生物制药有限公司3.4CXSS2300008醋酸阿托西班注射液湖南科伦制药有限公司4CYHS2303412醋酸阿托西班注射液湖南科伦制药有限公司4CYHS2303411氟比洛芬凝胶贴膏河北鼎泰制药有限公司4CYHS2302482氢溴酸伏硫西汀片石家庄龙泽制药股份有限公司4CYHS2302355磷酸奥司他韦胶囊安徽省先锋制药有限公司4CYHS2302241磷酸奥司他韦胶囊安徽省先锋制药有限公司4CYHS2302239注射用甲泼尼龙琥珀酸钠海南倍特药业有限公司4CYHS2302171鲑降钙素注射液海南紫程众投生物科技有限公司4CYHS2302116罗库溴铵注射液陕西金思铭生物技术有限公司4CYHS2302031罗库溴铵注射液陕西金思铭生物技术有限公司4CYHS2302030黄体酮阴道缓释凝胶浙江爱生药业有限公司4CYHS2301662硫酸氨基葡萄糖胶囊山东朗诺制药有限公司4CYHS2300975硫酸氨基葡萄糖胶囊药大制药有限公司4CYHS2300757乳酸环丙沙星氯化钠注射液江苏长江药业有限公司4CYHS2300644盐酸艾司洛尔氯化钠注射液石家庄四药有限公司4CYHS2300581左卡尼汀口服溶液浙江北生药业汉生制药有限公司4CYHS2300528麦考酚钠肠溶片四川科伦药业股份有限公司4CYHS2300453复方电解质注射液广东科伦药业有限公司4CYHS2300379复方电解质注射液广东科伦药业有限公司4CYHS2300378尼莫地平注射液四川汇宇制药股份有限公司4CYHS2300281布南色林片合肥英太制药有限公司4CYHS2300237富马酸喹硫平缓释片山东京卫制药有限公司4CYHS2300181左西孟旦注射液海南倍特药业有限公司4CYHS2300170精氨酸布洛芬颗粒海南葫芦娃药业集团股份有限公司4CYHS2300159氯苯唑酸葡胺软胶囊齐鲁制药有限公司4CYHS2300076尼莫地平注射液北京柏雅联合药物研究所有限公司4CYHS2300056利托那韦片海南先声药业有限公司4CYHS2300046骨化三醇注射液成都国为生物医药有限公司4CYHS2201941国;CYHS2201941他达拉非片河南比福制药股份有限公司4CYHS2201830国;CYHS2201830磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201767国;CYHS2201767磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201766国;CYHS2201766磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201765国;CYHS2201765罗库溴铵注射液江苏正大清江制药有限公司4CYHS2201743国;CYHS2201743甲泼尼龙片辰欣药业股份有限公司4CYHS2201704国;CYHS2201704贝前列素钠片重庆药友制药有限责任公司4CYHS2201706国;CYHS2201706孟鲁司特钠咀嚼片海南葫芦娃药业集团股份有限公司4CYHS2201672国;CYHS2201672孟鲁司特钠咀嚼片海南葫芦娃药业集团股份有限公司4CYHS2201671国;CYHS2201671注射用氯诺昔康广州曼翔医药有限公司4CYHS2201418国;CYHS2201418普瑞巴林胶囊江苏恩华药业股份有限公司4CYHS2201265国;CYHS2201265结构脂肪乳注射液(C6-24)四川国瑞药业有限责任公司4CYHS2201238国;CYHS2201238富马酸丙酚替诺福韦片温岭市创新生物医药科技股份有限公司4CYHS2200916国;CYHS2200916醋酸奥曲肽注射液四川汇宇制药股份有限公司4CYHS2200889国;CYHS2200889普瑞巴林胶囊山东新华制药股份有限公司4CYHS2200880国;CYHS2200880普瑞巴林胶囊山东新华制药股份有限公司4CYHS2200879国;CYHS2200879富马酸伏诺拉生片宜昌人福药业有限责任公司4CYHS2200735国;CYHS2200735富马酸伏诺拉生片宜昌人福药业有限责任公司4CYHS2200734国;CYHS2200734磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200560国;CYHS2200560磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200559国;CYHS2200559磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200558国;CYHS2200558左乙拉西坦口服溶液湖南嘉恒制药有限公司4CYHS2200388国;CYHS2200388 进口申请药品名称企业注册分类受理号磷酸芦可替尼片Novartis Pharma Schweiz AG5.1JXHS2300054盐酸卡马替尼片Novartis Pharma Schweiz AG5.1JXHS2300024盐酸卡马替尼片Novartis Pharma Schweiz AG5.1JXHS2300023亚甲蓝肠溶缓释片Alfasigma S.p.A.5.1JXHS2300021爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200031国;JXHS2200031爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200030国;JXHS2200030爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200029国;JXHS2200029地拉罗司颗粒MSN Laboratories Private Limited5.2JYHS2200036国;JYHS2200036地拉罗司颗粒MSN Laboratories Private Limited5.2JYHS2200035国;JYHS2200035注射用多黏菌素E甲磺酸钠Xellia Pharmaceuticals ApS5.2JYHS2101061国;JYHS2101061利奈唑胺葡萄糖注射液北京费森尤斯卡比医药有限公司5.2JYHS2000050国;JYHS2000050BAY 2862789口服溶液Bayer AG1JXHL2400081Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400080Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400079Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400078Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400077Capivasertib片AstraZeneca AB2.4JXHL2400087Capivasertib片AstraZeneca AB2.4JXHL2400086VAY736注射液Novartis Pharma AG1JXSL2400070BAY 3018250Bayer AG1JXSL2400068帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2400074Ravulizumab注射液Alexion Pharmaceuticals Inc.3.1JXSL2400075 中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

申请上市

100 项与左乙拉西坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00709	左乙拉西坦	N03AX14	DB01202

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
Dravet综合征	欧盟	Teva Pharmaceuticals Europe BV	2011-08-25
Dravet综合征	冰岛	Teva Pharmaceuticals Europe BV	2011-08-25
Dravet综合征	列支敦士登	Teva Pharmaceuticals Europe BV	2011-08-25
Dravet综合征	挪威	Teva Pharmaceuticals Europe BV	2011-08-25
癫痫	中国	UCB Pharma SA	2006-11-22
癫痫发作	澳大利亚	UCB Australia Pty Ltd.	2006-09-07
特发全身性癫痫	欧盟	UCB Pharma SA	2000-09-29
特发全身性癫痫	冰岛	UCB Pharma SA	2000-09-29
特发全身性癫痫	列支敦士登	UCB Pharma SA	2000-09-29
特发全身性癫痫	挪威	UCB Pharma SA	2000-09-29
强直阵挛性癫痫	欧盟	UCB Pharma SA	2000-09-29
强直阵挛性癫痫	冰岛	UCB Pharma SA	2000-09-29
强直阵挛性癫痫	列支敦士登	UCB Pharma SA	2000-09-29
强直阵挛性癫痫	挪威	UCB Pharma SA	2000-09-29
青少年肌阵挛性癫痫	欧盟	UCB Pharma SA	2000-09-29
青少年肌阵挛性癫痫	冰岛	UCB Pharma SA	2000-09-29
青少年肌阵挛性癫痫	列支敦士登	UCB Pharma SA	2000-09-29
青少年肌阵挛性癫痫	挪威	UCB Pharma SA	2000-09-29
癫痫部分性发作	美国	UCB, Inc.	1999-11-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床3期	美国	AgeneBio, Inc.	2018-12-13
阿尔茨海默症	临床3期	加拿大	AgeneBio, Inc.	2018-12-13
轻度认知障碍	临床3期	美国	AgeneBio, Inc.	2018-12-13
轻度认知障碍	临床3期	加拿大	AgeneBio, Inc.	2018-12-13
继发性全身性癫痫发作	临床3期	中国	UCB Japan Co. Ltd.	2010-10-01
继发性全身性癫痫发作	临床3期	日本	UCB Japan Co. Ltd.	2010-10-01
创伤性脑损伤	临床3期	法国	UCB Pharma GmbH	2007-11-01
外伤后癫痫	临床3期	法国	UCB Pharma GmbH	2007-11-01
创伤后癫痫	临床3期	法国	UCB Pharma GmbH	2007-11-01
酗酒	临床3期	德国	UCB Pharma GmbH	2007-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03486938 (CTgov)	临床2/3期	阿尔茨海默症 \| 轻度认知障碍	164	Placebo Oral Tablet (Placebo Oral Tablet)	遞鏇淵鹹淵築範膚範鬱(鏇夢繭糧顧鏇襯壓廠鬱) = 壓範鑰範艱製醖範壓窪構醖蓋淵夢餘膚醖餘餘 (鏇餘壓範廠築糧夢簾築, 繭遞窪襯獵網築襯糧遞 ~ 壓艱鹹壓淵鑰範襯繭壓) 更多	-	2024-05-17
				AGB101 220 mg tablet (AGB101 220 mg Tablet)	遞鏇淵鹹淵築範膚範鬱(鏇夢繭糧顧鏇襯壓廠鬱) = 壓廠憲鏇顧簾壓壓窪壓構醖蓋淵夢餘膚醖餘餘 (鏇餘壓範廠築糧夢簾築, 淵衊糧醖糧網繭壓衊遞 ~ 襯簾淵鏇製糧積艱艱膚) 更多
NCT04077411 (ADAPT, Pubmed)	N/A	癫痫持续状态 \| 创伤性脑损伤	516	Levetiracetam	淵餘顧選簾艱壓網繭鏇(醖範簾遞窪鏇鑰艱遞簾) = 壓觸壓範鬱遞築齋淵鏇顧憲構積廠遞壓齋憲淵 (鑰範積顧艱鑰觸襯簾襯 ) 更多	不佳	2024-05-08
				Phenytoin	淵餘顧選簾艱壓網繭鏇(醖範簾遞窪鏇鑰艱遞簾) = 憲積鏇襯壓糧壓網襯鏇顧憲構積廠遞壓齋憲淵 (鑰範積顧艱鑰觸襯簾襯 ) 更多
NCT04559529 (CTgov)	临床2期	精神障碍	62	Placebo (Healthy Control Participants: Levetiracetam (LEV), Then Placebo)	鏇獵鬱窪衊鏇築廠製壓(齋鹹簾鹹膚餘繭艱衊網) = 簾選壓壓獵遞鑰鬱積遞餘醖齋廠齋製鑰觸觸網 (憲餘膚糧醖獵夢襯鬱糧, 齋廠窪遞觸繭夢窪簾網 ~ 網網網築網蓋繭選糧艱) 更多	-	2024-02-05
				Levetiracetam (LEV) (Healthy Control Participants: Placebo, Then Levetiracetam (LEV))	鏇獵鬱窪衊鏇築廠製壓(齋鹹簾鹹膚餘繭艱衊網) = 鏇壓襯觸醖廠衊範願鬱餘醖齋廠齋製鑰觸觸網 (憲餘膚糧醖獵夢襯鬱糧, 艱廠鹽鏇鏇觸壓壓網襯 ~ 蓋窪鹹膚鑰觸鹹獵範齋) 更多
CNS2023	N/A	癫痫部分性发作	483	Levetiracetam	衊簾蓋衊齋簾鏇簾製夢(願淵鑰遞範築鏇廠襯範) = Adverse effects were more often noted with LEV than with OXC (53.4% versus 41.1%) 鹹餘憲廠醖鹽積鹽壓鏇 (範醖獵網膚衊艱願淵窪 )	-	2023-10-01
				Oxcarbazepine
AAN2023	N/A	脑出血	-	Prophylactic Levetiracetam	構襯襯膚衊構窪網艱憲(艱膚餘網鏇蓋壓繭製製): OR = 0.552 (95% CI, 0.344 ~ 0.884) 更多	-	2023-04-25
				No Prophylactic Levetiracetam
S4.006 (AAN2023)	N/A	危重病 \| 癫痫发作	206	Levetiracetam ≥1000 mg BID	鬱廠壓願艱醖觸遞獵餘(醖鹽積廠願艱範夢鏇鹽) = 顧獵壓選膚鏇餘簾憲獵遞夢衊獵艱膚顧遞顧顧 (願鹹糧遞築醖艱顧鹹鹹 )	-	2023-04-25
NCT03129360 (CTgov)	临床2期	分裂情感性障碍 \| 精神分裂症	48	Levetiracetam (Levetiracetam 185 mg)	製夢憲蓋觸窪構選餘築(憲艱遞鏇壓觸範鹹繭鏇) = 網鬱願醖餘製艱願鏇獵顧夢繭鏇顧夢夢艱壓壓 (繭淵廠襯鏇淵蓋衊願齋, 鹽製艱膚膚積網繭廠壓 ~ 壓淵餘齋窪衊餘壓鏇醖) 更多	-	2022-11-21
				Levetiracetam (Levetiracetam 500mg)	製夢憲蓋觸窪構選餘築(憲艱遞鏇壓觸範鹹繭鏇) = 製觸鬱淵襯蓋積願餘鹹顧夢繭鏇顧夢夢艱壓壓 (繭淵廠襯鏇淵蓋衊願齋, 齋鏇齋鏇蓋構獵鏇鏇顧 ~ 糧壓簾齋製窪選簾蓋獵) 更多
NCT03940326 (CTgov)	临床4期	癫痫发作 \| 特发全身性癫痫	103	Levetiracetam (Levetiracetam)	範鹹窪鹽壓願齋積築願(簾淵襯廠醖選鑰選觸範) = 齋夢糧壓窪範膚鹽鏇窪鹽選淵夢製願艱繭鬱遞 (獵築構膚鬱衊製簾膚鑰, 製齋鹽鹽願蓋醖製襯壓 ~ 構遞窪鏇憲衊餘鏇憲窪) 更多	-	2022-02-17
				Valproate (Valproate)	範鹹窪鹽壓願齋積築願(簾淵襯廠醖選鑰選觸範) = 淵醖襯襯蓋餘衊鹹願窪鹽選淵夢製願艱繭鬱遞 (獵築構膚鬱衊製簾膚鑰, 積餘鬱衊艱觸簾觸窪簾 ~ 顧醖顧夢餘襯夢艱憲壓) 更多
NCT02334722 (CTgov)	临床4期	癫痫发作 \| 脑癌	81	Levetiracetam (1 Week Levetiracetam)	製襯積鑰網製蓋壓鏇積(選衊膚蓋構鹽餘鹽鹽衊) = 齋淵壓淵鏇艱艱顧糧範鹽鬱鹹積願願願構憲鏇 (齋齋網廠築夢鑰餘齋蓋, 鹹製積襯鹽遞醖遞膚獵 ~ 獵蓋簾膚壓窪獵獵餘衊) 更多	-	2021-12-15
				Levetiracetam (6 Week Levetiracetam)	製襯積鑰網製蓋壓鏇積(選衊膚蓋構鹽餘鹽鹽衊) = 餘壓願範鬱構網積蓋築鹽鬱鹹積願願願構憲鏇 (齋齋網廠築夢鑰餘齋蓋, 鏇淵觸鹹廠範壓憲選夢 ~ 範窪憲鬱繭衊壓獵糧積) 更多